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Abstract
The number of elderly patients in the community with immunosuppressive conditions has increased progressively over recent decades.
We sought to determine the incidence, causative organisms and outcome of community-acquired pneumonia (CAP) occurring in immu-
nocompromised older patients. We prospectively compared cases of CAP in immunocompromised and non-immunocompromised
patients admitted to ﬁve public hospitals in three Spanish regions. Of 320 cases studied, 115 (36%) occurred in immunocompromised
patients, including: solid or hematological malignancy (97), corticosteroids or other immunosuppressive drugs (44), solid organ or stem
cell transplant (ﬁve), and other conditions (eight). The etiology was established in 44% of immunocompromised patients vs. 32% of non-
immunocompromised patients (p 0.03). Streptococcus pneumoniae was the most common causative organism in both groups (29% vs.
21%; p 0.08), followed by Legionella pneumophila (3% vs. 6%; p 0.01). Gram-negative bacilli were more frequent among immunocompro-
mised patients (5% vs. 0.5%; p <0.01), particularly Pseudomonas aeruginosa (3% vs. 0%; p 0.04). Nocardiosis was only observed in immu-
nocompromised patients (two cases). Bacteremia occurred similarly in the two groups. No signiﬁcant differences were found with
respect to ICU admission (8%, in both groups) or the length of stay (12.5 vs. 10.4 days). The early (<48 h) (3.5 vs. 0.5%; p 0.04) and
overall case-fatality rates (12% vs. 3%; p <0.01) were higher in immunocompromised patients. In conclusion, a substantial number of
older patients hospitalized for CAP are immunocompromised. Although relatively uncommon, CAP due to gram-negative bacilli, includ-
ing P. aeruginosa, is more frequent among these patients. CAP occurring in immunocompromised patients causes signiﬁcant morbidity
and mortality.
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Introduction
Community-acquired pneumonia (CAP) is the third-most-fre-
quent hospital diagnosis among patients aged ‡65 years and
the sixth leading cause of death in developed countries. In
Spain, the incidence of CAP in adults is 2–10 cases/1000
inhabitants/year; but increases to 25–35 cases/1000 inhabit-
ants in people aged >70 years. At least 20% of patients with
CAP require hospitalization. The mortality is 10–25%, and is
particularly high in the elderly [1] and patients requiring
intensive care unit (ICU) admission [2].
The number of elderly patients in the community with
immunosuppressive conditions has increased progressively
over recent decades [3]. Even though the clinical aspects of
nosocomial pneumonia in immunosuppressed patients are
well documented, there are few studies of CAP in patients
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aged ‡65 years. Moreover, immunocompromised patients
have been systematically excluded from prospective CAP
studies. In addition, the Infectious Diseases Society of Amer-
ica and the American Thoracic Society consensus guidelines
on the management of CAP in adults do not include recom-
mendations for immunocompromised patients [4].
We sought to determine the incidence, causative organ-
isms and outcome of CAP in immunocompromised older
patients.
Methods
Setting, participants, and study design
A prospective, observational, multicenter study was con-
ducted in patients aged ‡65 years hospitalized with CAP
through the emergency departments of ﬁve public hospitals
(providing universal free care to the whole population) in
three Spanish regions (Aragon, Catalonia, and Galicia)
between May 1, 2005 and January 31, 2007. Exclusion criteria
were permanent nursing home residence, patients with nos-
ocomial pneumonia (onset ‡2 days after hospital admission),
patients whose initial diagnosis of pneumonia was not con-
ﬁrmed during the hospital stay, and CAP due to fungal or
mycobacterial etiology.
We compared causative organisms and outcomes in cases
of CAP in immunocompromised and non-immunocompro-
mised patients. Outcomes variables analyzed were ICU
admission, length of stay, and early and overall case-fatality
rates. The ethics committee of each participating hospital
approved the study. Oral consent was obtained from all par-
ticipants or a close relative.
Clinical assessment, antibiotic therapy, and follow-up
At the initial visit, before starting empirical antibiotic therapy,
participants underwent a complete clinical history and physi-
cal examination. Basic chemistry and hematologic tests, arte-
rial blood gas determinations, and chest radiography were
performed. There was not an established protocol for
microbiological work up in the study. The microbiological
tests were those routinely used in clinical practice at each
center. Microbiological studies mainly included two sets of
blood cultures and sputum Gram stain and culture when
available. Urinary antigen detection for S. pneumoniae was
performed as indicated by attending physician. Participants
were stratiﬁed into risk classes and the validated prediction
rule calculated according to the Pneumonia Severity Index
(PSI) score, as previously described [5].
Empirical antibiotic therapy was administered according to
individual hospital guidelines. One or more study investigators
saw participants daily during their hospital stay and recorded
clinical and microbiological data. The investigators made no
decisions about ICU admission or hospital discharge, which
were always made by attending physicians. A long-term fol-
low-up visit was made c. 1 month after hospital discharge. All
assessments were made using a standard protocol form with
a checklist of items.
Deﬁnitions
Hospitalization criteria have been previously described [6].
Pneumonia was deﬁned as a new inﬁltrate on chest X-ray
and one or more of the following symptoms or signs of
acute lower respiratory tract infection: cough, chest pain,
fever >38C, temperature <35C, and dyspnea within the
previous 24 h [7]. Immunosuppression was considered to be
present when ‡1 of the following conditions were docu-
mented: underlying solid or hematological malignancy, solid
organ or stem cell transplant, seropositivity for human
immunodeﬁciency virus (HIV), splenectomy, radiotherapy,
administration of corticosteroids (‡20 mg/day during
2 weeks in the last month) and other immunosuppressive
drugs, and congenital or acquired immune deﬁciency disor-
der. The immunocompromised state had to be active at the
time of patient’s inclusion. A neoplastic disease was deﬁned
as active if it required medical or surgical intervention within
the last year or if no-treatable metastases were present at
time of the inclusion into the study. Radiotherapy was con-
sidered within the last 3 months and chemotherapy or corti-
costeroids within 1 month.
Length of stay (LOS) was measured in days and was calcu-
lated as the time from admission to the date of hospital dis-
charge. The early case fatality-rate was deﬁned as death
from any cause £48 h after hospitalization. The overall case-
fatality rate was deﬁned as death from any cause within
30 days of hospitalization.
Microbiological studies
Pathogens in blood, normally sterile ﬂuids, sputum and other
samples were investigated using standard microbiological
procedures. Isolation of Legionella was attempted in sputum
and other respiratory samples by using selective media (buf-
fered charcoal-yeast extract agar). S. pneumoniae antigen in
urine was detected using rapid immunochromatography
(NOW assay, Binax, Inc., Portland, ME, USA). L. pneumophila
serogroup 1 antigen in urine was detected using immuno-
chromatography (NOW Legionella Urinary Antigen, Binax,
Inc.). Standard serological methods were used to determine
antibodies against the following pathogens: Mycoplasma pneu-
moniae (indirect agglutination), Chlamydia psittaci [immunoﬂu-
orescence (IF)], Chlamydia pneumoniae (micro-IF), Coxiella
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burnetii (IF), and L. pneumophila (serogroups 1–6) [enzyme
immunoassay (EIA)]. Four-fold rises in the titer of IgG anti-
bodies or detection of IgM antibodies or both were consid-
ered diagnostic.
Statistical analysis
Outcome variables were compared in immunocompromised
and non-immunocompromised patients. Categorical variables
were analyzed using the Chi-square test or Fisher’s exact
test, as appropriate. Continuous variables were analyzed by
non-parametric tests after verifying a non-normal distribu-
tion. All statistical tests were two-tailed and p <0.05 was
deemed signiﬁcant. The analysis was made using the SPSS
v17.0 (SPSS Inc., Chicago, IL, USA) statistical package.
Results
A total of 320 patients aged ‡65 years hospitalized with CAP
were studied, 115 (36%) of whom were immunocompro-
mised and 205 (64%) non-immunocompromised.
Patients’ clinical and microbiological characteristics are
shown in Table 1. The underlying immunosuppressive condi-
tions were ‡1 of the following: solid or hematological malig-
nancy in 97 patients, pharmacologic immunosuppression
(corticosteroids or cytostatic drugs) in 44, solid organ or
stem cell transplant in ﬁve and other conditions in eight.
There were no HIV-infected patients. Of 26 patients consid-
ered to be immunocompromised to corticosteroid therapy,
only 9 (34.6%) had chronic obstructive pulmonary disease.
Immunocompromised patients were mainly male and had a
younger mean age than non-immunocompromised patients.
There were more cases of previous pneumonia in immuno-
compromised patients. No difference was observed in the
frequency of previous pneumococcal and seasonal inﬂuenza
vaccination. The mean duration of symptoms before hospital-
ization in immunocompromised and non-immunocompro-
mised patients was 4.9 ± 6 vs. 5.1 ± 4.3 days, respectively
(p 0.73). Immunocompromised patients were more often
classiﬁed into the PSI high risk classes.
An etiologic diagnosis was made in 116 (36.3%) patients:
50 (44%) were immunocompromised and 66 (32%) non-
immunocompromised (p 0.03). Blood cultures were obtained
more often in immunocompromised patients. Bacteremia
was detected in 14 (12.2%) immunocompromised and 19
(9.3%) non-immunocompromised patients (p 0.41).
TABLE 1. Clinical and microbiolog-
ical characteristics of cap in
immunocompromised and non-
immunocompromised patients
Variable n (%) Immunocompromised
patients (n = 115)
Non-immunocompromised
patients (n = 205)
p
Sex (male) 83 (72.2) 110 (53.7) <0.01
Mean age (years) 75.2 ± 6.5 77.5 ± 7.8 <0.01
Previous pneumonia 28 (25.2) 32 (16.2) 0.05
Pneumococcal vaccine 55 (47.8) 81 (39.5) 0.15
Seasonal inﬂuenza vaccine 66 (57.4) 121 (59.0) 0.78
Current smoker 49 (7.9) 16 (7.8) 0.96
Former smokers 45 (47.0) 73 (35.6) 0.05
Alcohol abuse 7 (7.6) 19 (10.4) 0.45
PSI risk classesa <0.01
II 0 (0) 27 (13.2)
III 19 (16.5) 69 (33.7)
IV 52 (45.2) 76 (37.1)
V 31 (27) 15 (7.3)
Causative agents
S. pneumoniae 33 (28.7) 43 (20.9) 0.08
H. inﬂuenzae 2 (1.7) 2 (0.98) 0.45
L. pneumophila 3 (2.6) 12 (5.8) 0.15
P. aeruginosa 3 (2.6) 0 (0) 0.04
Nocardia spp. 2 (1.7) 0 (0) 0.13
Gram-negative bacilli 6 (5.2) 1 (0.5) 0.01
Atypical and Legionella spp 4 (3.5) 16 (7.8) 0.09
Unknown etiology 65 (56.5) 139 (67.8) 0.03
Diagnostic methods
Blood cultures 87 (76.3) 119(58) <0.01
Sputum culture 39 (33.9) 73 (35.6) 0.76
Sputum culture + 15 (38.5) 13 (17.8) 0.02
Legionella antigen 68 (59.1) 152 (74.1) <0.01
Legionella antigen + 3 (4.4) 12 (7.9) 0.40
Pneumococcal antigen 86 (74.8) 171 (83.4) 0.06
Pneumococcal antigen + 27 (31.4) 31 (18.1) 0.01
Invasive procedures 7 (6.09) 16 (7.80) 0.57
Fibrobronchial aspirate 2 (1.74) 2 (0.97)
Protected specimen brush 1 (0.87) 0 (0)
Bronchoalveolar lavage 2 (1.74) 1 (0.49)
Pleurocentesis 2 (1.74) 12 (5.85)
Transthoracic needle aspiration 0 (0) 1 (0.49)
aPSI scores were missing in 13 immunocompromised patients and in 18 non-immunocompromised patients
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An etiologic diagnosis was made by bronchoscopy (includ-
ing ﬁbrobronchial aspirate, protected specimen brush, and
bronchoalveolar lavage) in 5 (4.3%) immunocompromised
and 3 (1.4%) non-immunocompromised episodes.
The most-frequent microorganisms causing CAP were
S. pneumoniae (76, 65.6%), L. pneumophila (15, 12.9%) and
H. inﬂuenzae (4, 3.5%), with no differences between groups.
Gram-negative bacilli were isolated more often in immuno-
compromised patients (5.2% vs 0.5%; p 0.01). P. aeruginosa
and Nocardia spp. were isolated only in immunocompromised
patients (three and two, respectively). There was one case
of Staphylococcus aureus pneumonia and viral pneumonia due
to respiratory syncytial virus, respectively, both in immuno-
compromised patients.
Table 2 shows the empirical antimicrobial therapy and
outcomes of CAP in the two groups. Most patients were
given initial antibiotic monotherapy (70; 60.9% vs. 127; 62%).
Levoﬂoxacin was the most-frequently administered drug in
both groups (29; 25.2% vs. 64; 31.2%). The mean number of
treatment days was 13.6 vs. 12.8 days, respectively (p 0.36).
The frequency of ICU admission, mechanical ventilation and
the length of hospital stay did not differ between groups.
The early (<48 h) (3.5% vs. 0.5%; p 0.04) and overall case-
fatality rates were higher in immunocompromised patients
(12% vs. 3%; p <0.01). All three cases of pneumonia caused
by P. aeruginosa were complicated by bacteremia, resulting in
two deaths.
Discussion
A substantial number of elderly patients hospitalized for CAP
in the present study were immunocompromised due to vari-
ous underlying conditions. This probably reﬂects a change in
our indwelling population, with larger numbers of older
immunocompromised patients, due mainly to transplantation,
malignancy, corticosteroids and other immunosuppressive
drugs. In a recent population-based study of CAP in older
adults [3], the incidence rate of CAP was almost three-fold
higher among immunocompromised patients than in immu-
nocompetent subjects. A case-control study investigating the
risk of hospitalization for pneumonia in older adults in Can-
ada found that the use of immunosuppressant medication
was an important risk factor for CAP, with an OR = 15.13
(95% CI, 4.7–48.3; p <0.05) in the multivariate analysis [8].
The impact of the immune status in CAP has been little
studied [9–13]. A prospective 1-year study by Mundy et al. in
1990 evaluated the immune status of hospitalized patients
with CAP. Concurrent immunosuppression was observed in
57% of the 221 patients, 180 of whom were HIV-infected.
These results are consistent with the disproportionate
impact of HIV-infection on admissions for CAP two decades
ago, compared with other conditions. Although there has
been a substantial decline in the number of HIV-infected
patients admitted to hospital due to CAP over the last
15 years, the older age the patients in our study may explain,
in part, the absence of HIV-infections.
An etiological diagnosis was made in a relatively-low pro-
portion of our patients compared with other recent studies
[1]. The rate of identiﬁcation of a causative agent of CAP in
clinical practice is low and the etiology may remain obscure
in more than half of all cases [14]. A multicenter study in the
USA that assessed routine clinical practice in cases of CAP
found that the cause was identiﬁed in only 25% of cases
[15]. Some studies have reported even-lower diagnostic
rates in the elderly, with identiﬁcation of causative organisms
in 5–20% of CAP cases [16,17], perhaps indicating a reluc-
tance to perform invasive procedures in this age-group.
The distribution of microorganisms was essentially the
same in immunocompromised and non-immunocompromised
patients. As expected [18], S. pneumoniae, which is the most
frequent cause of CAP in a wide variety of immunocompro-
TABLE 2. Comparison of empirical
antimicrobial therapy and clinical
outcomes in immunocompromised
and non-immunocompromised
patients with CAP
Variable Immunocompromised
patients (n = 115)
Non-immunocompromised
patients (n = 205)
p
Antibiotic monotherapy n (%) 70 (60.9) 127 (62.0) 0.94
Levoﬂoxacin 29 (25.2) 64 (31.2) 0.31
Amoxicillin-clavulanate 10 (8.7) 47 (22.9) <0.01
Ceftriaxone 15 (13.0) 12 (5.9) 0.03
Piperacillin-tazobactam 6(5.2) 0(0) <0.01
Combination therapy n (%)
Ceftriaxone + levoﬂoxacin 21 (18.3) 36 (17.6) 0.88
Ceftriaxone + azithromycin 5 (4.3) 25 (12.2) 0.02
Amoxicillin-clavulanate + azithromycin 1 (0.9) 9 (4.4) 0.08
ICU admission n (%) 9 (7.8) 16 (7.8) 0.99
Mechanical ventilation n (%) 6 (5.2) 6 (2.9) 0.30
Bacteremia n (%) 14(12.2) 19(9.3) 0.41
Pleural effusion n (%) 2 (1.7) 10 (4.9) 0.16
Length of stay (days) 12.5 ± 12.2 10.4 ± 10.1 0.10
Early mortality (£48 h) n (%) 4 (3.5) 1 (0.5) 0.04
Overall mortality n (%) 14 (12.2) 7 (3.4) <0.01
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mised patients, was the most-common etiological agent,
independently of the immune status [11,12,19–22].
Pseudomonas aeruginosa pneumonia occurs rarely, if at all,
in non-immunocompromised patients. In a large, prospective,
population-based study of 5130 patients in the German
Competence Network for Community-Acquired Pneumonia
(CAPNETZ study) [23], the incidence of Enterobacteriaceae
and P. aeruginosa in patients with CAP was 1.3% and 0.4%,
respectively. In our study, gram-negative bacilli were signiﬁ-
cantly more-frequent in immunocompromised than in non-
immunocompromised patients and CAP due to P. aeruginosa
occurred only among immunocompromised patients.
Staphylococcus aureus, and particularly methicillin-resistant
strains, are a challenge in most hospitals and a growing cause
for concern in community-onset pneumonia in the United
States [24–26]. The lack of virus detection in our patients
may be explained by the lack of routine investigation of
respiratory viruses. In a recent Spanish study [11] speciﬁcally
addressing the incidence of viral CAP in immunocompro-
mised patients, which required a nasopharyngeal swab for
respiratory viruses, an etiologic diagnosis was made in 66%
of cases and the most-frequent pathogen detected was
S. pneumoniae (48%), followed by rhinovirus (18%).
A recent study [27] found a substantial reduction in mor-
tality among elderly patients with CAP between 1987 and
2005. The authors suggested that a large part of this reduc-
tion is explained by increased vaccination rates and the use
of guideline-concordant antibiotics. The poorer prognosis
observed in our immunocompromised patients could be
related to greater disease severity, as demonstrated by the
PSI risk class at admission, different etiological agents and
the host’s suppressed immune response. In the CAPNETZ
study [23], 30-day mortality was signiﬁcantly higher in
patients with pneumonia caused by Enterobacteriaceae and
P. aeruginosa. A study [13] analyzing the utility of PSI in
immunocompromised patients admitted for CAP, found an
overall mortality rate of 14%. Patients with HIV-infection,
solid organ transplantation or treatment with immunosup-
pressive drugs had an in-hospital mortality of 4.3%, whereas
patients with hematological malignancies, chemotherapy,
chest radiation or bone marrow transplantation had a rate
of 20%.
Our study has some limitations. Conventional microbio-
logical tests were not performed in all patients. Moreover,
information on the proportion of fungal or mycobacterial
CAP was not available. However, we think that tuberculosis
and fungal infections represent two distinctive clinical set-
tings. The appropriateness of empirical therapy could not be
evaluated in all centers and the inﬂuence of empirical therapy
on the outcome could not therefore be established. Finally,
our results are limited to cases that required hospitalization
and may not be applicable to cases treated as outpatients.
In conclusion, our study shows that a substantial number
of older patients hospitalized for CAP are immunocompro-
mised. Although relatively uncommon, CAP due to gram-
negative bacilli, including P. aeruginosa, is more frequent
among these patients. CAP occurring in immunocompro-
mised patients causes signiﬁcant morbidity and case-fatality
rates.
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